Q2 FY2026 EarningsQ2 FY26 results for GUTS were mixed relative to consensus: GAAP EPS of -$0.16 missed the -$0.13 mean estimate, driven by non-cash warrant liability adjustments, while operating loss of -$19.1M was narrower than the expected -$21.4M EBIT loss due to disciplined R&D spending. The company reported zero revenue, in-line with its clinical-stage status. Management reiterated a cash runway into early 2027 and confirmed pivotal REMAIN-1 data readout remains on track for early Q4 2026.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Fractyl Health(GUTS) the EBIT is -19.1 M (+26.78%), Beat estimate;the EPS is -0.16 (+71.93%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
Revenue
TBA--
0.00B--
----
EBITExceed expectations
-0.02B26.78%
-0.02B18.00%
+0.00B8.78%
EPSMiss expectations
-0.1671.93%
-0.132576.75%
-0.02754.82%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf